Fig. 2: DP2 antagonism or DP1 agonism decreases lung TGF-β1 expression and increases EGF expression. | Nature Communications

Fig. 2: DP2 antagonism or DP1 agonism decreases lung TGF-β1 expression and increases EGF expression.

From: Dual therapy with corticosteroid ablates the beneficial effect of DP2 antagonism in chronic experimental asthma

Fig. 2

A TGF-β1 immunoreactivity (red coloration). Scale bars = 50 µm. B, C Quantification of TGF-β1 immunoreactivity around the airways. D, E Lung TGF-β1 levels in homogenates. F, G Lung EGF levels in homogenates. H EGF immunoreactivity (red coloration). Scale bars = 50 µm. I, J Quantification of EGF immunoreactivity in airway epithelial cells (AECs). Data are presented as mean ± SEM or box-and-whisker plots showing individual data points with the boxes representing quartiles and whiskers indicating the range and are pooled data from two independent experiments (n = 4–9 mice per group). Statistical significance between different time points or different groups was determined using one-way ANOVA with Dunnett’s multiple comparison test. ** denotes p < 0.01 and *** denotes p < 0.001 compared to vehicle group. ## denotes p < 0.01 and ### denotes p < 0.001 compared to RV-infected group at corresponding time point. Source data are provided as a Source Data file.

Back to article page